Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;6:10. doi: 10.1038/s41698-022-00253-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Depiction of a tumor with a compartmentalized spatial architecture. These tumors have decreased mixing between immune cells and neoplastic tumor cells and tend to contain greater immune cell density, specifically cells involved in antigen presentation, as well as increased density of αSMA⁺ mesenchymal cells. The αSMA⁺ cells present tend to be neighbored by CD4⁺ T helper cells and B cells, as well as other αSMA⁺ cells. Compartmentalized primary tumors were found to be associated with longer progression-free survival. b Depiction of a tumor with a mixed spatial architecture. These tumors contain increased mixing between immune cells and neoplastic tumor cells and tend to contain increased neoplastic tumor cells, as well as increased PD-1-positive lymphocytes. The αSMA⁺ cells present tend to be neighbored by neoplastic tumor cells, other immune cells, many of which are CD163⁺ or are mast cells, and granulocytes. Mixed primary tumors were found to be associated with shorter progression free survival and later TNM stage. This figure was created using BioRender.com.